From this page You could reach all the figures at the Turkish Journal of Hematology archive.
You could save all the imges by the save as button and paste them to office documents.
Please use the articles details for reference.
You could see the abstracts of the images from the link above the image.
Search In Pictures
Search In Articles
Not null!
Search term(s) must be at least 3 characters!
All Types
Microscope display
FISH display
(MDCT),MRI,radiologic
Dermatologic
Other
32 records found...
Ertugrul Cagri Bolek, Gursel Gunes, Umit Yavuz Malkan, Tuncay Aslan, Sezgin Etgul, Okan Yayar / Hacettepe University School of Medicine, Hematology
Pappenheimer bodies in erythrocytes (myelofibrosis)
The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms
Figure 1: JAK2V617F-positivity and bone marrow fibrosis
The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms
Figure 2: JAK2V617F-positivity according to different grades of bone marrow fibrosis
Central retinal artery occlusion as the presenting sign of essential thrombocythemia
Figure 1. The fundus of the right eye at presentation shows the cherry-red spot and attenuated arterioles
Central retinal artery occlusion as the presenting sign of essential thrombocythemia
Figure 2. Coronal oblique computed tomographic angiography of the entire supra-aortic region. The right common carotid artery is occluded 2 cm distal to its origin (arrow). The right internal carotid artery is also occluded; right intracranial carotid circulation is provided by collateral pathways
Complex cytogenetic findings in the bone marrow of a chronic idiopathic myelofibrosis patient
Figure 1. Karyotype of the patient: 46,XY,del(9)(q22q34),t(8;17;21)(q22;q21;q22)
Complex cytogenetic findings in the bone marrow of a chronic idiopathic myelofibrosis patient
Figure 2. a: Metaphase spread of the patient; relevant chromosomes are marked with arrows b: The same metaphase after fluorescence in situ hybridization with Whole Chromosome Probe 8 Spectrum Orange (Vysis, USA); relevant chromosomes are marked with arrows
Complex cytogenetic findings in the bone marrow of a chronic idiopathic myelofibrosis patient
Figure 3. a: Metaphase spread of the patient; relevant chromosomes are marked with arrows b: The same metaphase after fluorescence in situ hybridization with Whole Chromosome Probe 17 Spectrum Orange (Vysis, USA); relevant chromosomes are marked with arrows
Enhanced platelet adhesion in essential thrombocythemia after in vitro activation
Figure 1. Platelet adhesion to albumin (a), collagen (b), fibrinogen (c), and fibronectin (d) was significantly increased by ADP (1 and 10 µmol/L) for both controls and ET-platelets. A dose-response relationship was seen on all surfaces for ET-platelets, but only on albumin and fibronectin for controls. Differences in basal adhesion (solvent) between the three groups were not significant. Data are presented as mean+SD. Filled bars = Controls (n = 11 except for fibronectin where n = 10, age range: 31-63 years), open bars = Age-matched patients (n = 14, age range: 30-66 years), patterned bars = Patients ? 67 years (n = 16, age range: 67-87 years). ns = not significant, **p
Enhanced platelet adhesion in essential thrombocythemia after in vitro activation
Figure 2. The combination of 0.1 µmol/L adrenaline (Adr) and 10 µmol/L LPA increased platelet adhesion synergistically to albumin for both ETplatelets and controls. Data are presented as mean+SD. Filled bars = Controls (n = 11, age range: 31-63 years), open bars = Age-matched patients (n = 14, age range: 30-66 years), patterned bars = Patients ? 67 years (n = 16, age range: 67-87 years). ns = not significant, **p
1
2
3
4
Next Page >
Last Page >>
Sayfa 1 / 4 -- Toplam Kayıt 32 -- Listelenen kayıt sayısı 10
Not null!
Search term(s) must be at least 3 characters!
All Columns
Referance Numbers
Titles
Summeries
Keywords
0 records found...
1
Sayfa 1 / 1 -- Toplam Kayıt 0 -- Listelenen kayıt sayısı 0
AUTOIMMUNE DISORDERS (0 / 0)
Autoimmune Hemolytic Anemias (0 / 0)
Others (0 / 0)
CHEMOKINES (0 / 8)
Chemokines and cytokines (0 / 0)
Chemotactic Effects (0 / 2)
Other Effects (0 / 0)
Hematopoietic (0 / 0)
Angiogenic (0 / 0)
HIV Effects (0 / 6)
Regulation of Receptor Expression (0 / 0)
Signal Transduction (0 / 0)
CYTOGENETICS (0 / 2)
Gene Polymorphisms (0 / 2)
HEMOSTASIS (0 / 87)
Platelet and the vessel wall (0 / 13)
Blood coagulation (0 / 24)
Biology of hemostatic proteins (0 / 4)
Fibrinogen (0 / 0)
Vitamin K-dependent coagulation factors (0 / 0)
Coagulation factors (0 / 4)
Factor VIII-Factor IX-Factor XI (0 / 8)
Other coagulation factors (0 / 0)
Protein C anticoagulant pathway (0 / 0)
Other coagulation inhibitors (0 / 0)
Fibrinolytic enzymes and inhibitors (0 / 0)
Thrombotic Disorders (0 / 36)
Inherited coagulopathies (0 / 4)
Antithrombin deficiency (0 / 0)
Protein C deficiency (0 / 4)
Protein S deficiency (0 / 0)
Factor V Leiden mutation (0 / 0)
Prothrombin t20210A Mutation (0 / 0)
Acquired coagulation disorders (0 / 5)
Disseminated intravascular coagulation (0 / 5)
Liver Disease (0 / 0)
Vitamin K Deficiency (0 / 0)
Massive Transfusion Coagulapathies (0 / 0)
Acquired Inhibitors of coagulation proteins (0 / 0)
Replacement therapies (0 / 0)
Other therapies (0 / 0)
Cancer and thrombosis (0 / 3)
Antiphospholipid antibody syndrome (0 / 1)
Thrombotic thrombocytopenic purpura (0 / 1)
Heparin-induced thrombocytopenia (0 / 0)
Venous thromboembolism treatment (0 / 0)
Arterial thrombosis (0 / 13)
Antithrombotic therapy (0 / 6)
Heparin, low molecular weight heparin (0 / 3)
Direct thrombin inhibitors (0 / 0)
Oral anticoagulants (0 / 3)
Antifibrinolytic therapy (0 / 0)
Endothelium (0 / 1)
HEMATOLOGİC MANIFESTATİONS OF SYSTEMİC DISEASES (0 / 46)
GENE THERAPY (0 / 0)
HEMATOPOIESIS (0 / 8)
Stem and Primitive Progenitor Cells (0 / 0)
Red Blood Cells (0 / 0)
Granulocytes (0 / 1)
Lymphocytes (0 / 3)
Monocytes (0 / 0)
Eosinophilia (0 / 1)
Basophilia (0 / 0)
Megakaryocytes (0 / 3)
Mast Cells (0 / 0)
IRON (0 / 13)
Iron Deficiency (0 / 10)
Iron Overload (0 / 3)
IMMUNOLOGY (0 / 22)
Innate Immunity (0 / 0)
Immunoglobulins (0 / 16)
Antigen Recognition by T Lymphocytes (0 / 0)
The Development of B Lymphocytes (0 / 0)
T-Cell Mediated Immunity (0 / 0)
The Humoral Immune Response (0 / 0)
Immundeficiency dieases (0 / 0)
Allergy and Hypersensitivity (0 / 3)
Immune Response Disorder (0 / 3)
Autoimmunity: responses to self antigens (0 / 2)
Transplant rejection: responses to alloantigens (0 / 0)
Tumor immunology (0 / 0)
Lymphoid Cells Neoplasms (0 / 0)
B-cell neoplasms (0 / 0)
T-cell neoplasms (0 / 0)
NK cell neoplasms (0 / 0)
Others (0 / 0)
INFECTION (0 / 16)
Febril Neutropenia (0 / 6)
Viral Infections (0 / 1)
Fungan Infections (0 / 1)
Bacterial Infections (0 / 2)
Parasitic Infections (0 / 2)
MARROW (0 / 9)
Physiology of Hematopoiesis (0 / 5)
Bone Marrow Failure (0 / 1)
Acquired Aplastic Anemia (0 / 3)
Fanconi Anemia (0 / 0)
Inherited Pure Red Cell Anemia (0 / 0)
Acquired Pure Red Cell Anemia (0 / 0)
STEM CELL TRANSPLANTATION (0 / 54)
Stem cell physiology (0 / 9)
Stem cell mobilization (0 / 0)
Immunologic tolerance (0 / 0)
Graft rejection (0 / 0)
Conditioning regimen (0 / 0)
Allo transplantation (0 / 18)
Auto transplantation (0 / 2)
Non myeloablative (0 / 0)
Organ Specific Toxicity (0 / 3)
Clinical Care of Graft-Versus-Host Disease (0 / 10)
Acute GVHD (0 / 0)
Chronic GVHD (0 / 10)
NEOPLASIA (0 / 354)
Pediatric hematologic Malignancies (0 / 3)
Pediatric Leukemia (0 / 8)
Pediatric Lymphomas (0 / 2)
Acute Leukemia (0 / 12)
Acute Lymphoblastic Leukemia (0 / 36)
Acute Myeloblastic Leukemia (0 / 66)
Myelodysplastic Syndromes (0 / 3)
Chronic Leukemia (0 / 0)
Chronic Lymphocytic Leukemia (0 / 7)
Chronic Myeloid Leukemia (0 / 18)
Other Lymphoproliferative Disorders (0 / 2)
Other Leukemias (0 / 12)
Lymphomas (0 / 37)
Hodgkin Lymphoma (0 / 10)
Non Hodgkin Lymphoma (0 / 45)
Chronic Myeloproliferative Neoplasms (0 / 32)
Pharmacotherapeutics (0 / 3)
Oncogenes (0 / 0)
Multipl myeloma (0 / 45)
Plasmacytoma (0 / 2)
Cryoglobulinemia (0 / 2)
Plasma Cell Disorders (0 / 7)
PHAGOCYTES (0 / 16)
Neutrophils (0 / 4)
Monocytes and Macrophages (0 / 3)
Eosinophils (0 / 3)
Basophils (0 / 0)
Mast cells (0 / 0)
Dendritic cells (0 / 6)
Chemotaxis (0 / 0)
Antigen presentation (0 / 0)
Phagocytosis, cytotoxicity (0 / 2)
PLATELETS (0 / 34)
Physiology of Normal Platelets (0 / 10)
Signal Transduction (0 / 0)
Disorders of Platelets (0 / 12)
von Willebrand Disease (0 / 7)
Acquired Platelet Disorders (0 / 0)
Autoimmune and Alloimmune platelet disorders (0 / 2)
RED CELLS (2 / 92)
Hemoglobin disorders (0 / 6)
Anemia (2 / 40)
Nutritional anemia (0 / 9)
iron, cobalamin, folate deficiency (0 / 7)
Fanconi Anemia (0 / 1)
Aplastic Anemia (0 / 6)
Myeloproliferative and myelodysplasia (0 / 0)
Immune Hemolytic anemias (2 / 12)
Red cell membrane disorders (0 / 7)
Paroxymal Nocturnal hemoglobin (PNH) (0 / 0)
Enzyme disorders (0 / 0)
Sickle cell anemia (0 / 4)
Thalassemia (0 / 19)
Other hemoglobinopathies (0 / 11)
Polycythemia (0 / 4)
Polycythemia Vera (0 / 3)
Secondary Polycythemia (0 / 0)
WHITE CELLS (0 / 4)
Congenital Neutropenia (0 / 3)
Acquired Neutropenia (0 / 0)
Leucocyte Function Disorders (0 / 0)
Lymphocytes (0 / 0)
SUPPORTIVE CARE (0 / 0)
MOLECULAR HEMATOLOGY (0 / 6)
TRANSFUSION MEDICINE (0 / 10)
Apheresis (0 / 4)
Red Blood Cells (0 / 3)
White cell transfusions (0 / 1)
Platelet transfusions (0 / 0)
VASCULAR BIOLOGY (0 / 0)
OTHER (325 / 85)
FLOW CYTOMETRY (0 / 2)
STORAGE DISORDERS (0 / 14)
Spleen (0 / 1)
Experimental Hematology (0 / 3)
IRRADIATION (0 / 3)
Copyright © 2024 Atlas of Hematology. All rights reserved.
LookUs
&
OnlineMakale